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Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaning-
ful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-
positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is
a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin
or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients
with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The pri-
mary end point is progression-free survival by independent review. Key secondary end points include
overall survival, response rate, duration of response and progression-free survival.
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Lung cancer is the leading cause of cancer death worldwide, accounting for 2.09 million new cases and 1.76 million
deaths in 2018 [1]. The majority (80–85%) of lung cancers are classified as non-small-cell lung cancer (NSCLC),
of which adenocarcinoma is the most common histologic subtype [2,3]. While outcomes for patients diagnosed
with advanced disease remain poor, treatment for NSCLC has recently been revolutionized by the advent of
immunotherapy, using checkpoint inhibitors as well as targeted therapies directed at actionable oncogenic drivers [4].
The standard of care (SOC) first-line treatment for patients with NSCLC has historically been platinum-based
chemotherapy [5]. Recent studies have demonstrated that the addition of an immune checkpoint inhibitor (anti-
PD-1 or PD-L1 antibody) to platinum-based regimens improve response rates, progression-free survival (PFS),
and overall survival (OS), both for nonsquamous [6–8] and squamous NSCLC [5,7]. For patients with high PD-L1
expression (tumor proportion score of 50% or greater), monotherapy with a PD-L1 inhibitor is an option [9].
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Figure 1. Schematic illustration of RET gene rearrangements identified in non-small-cell lung cancer.
Recently, the immunotherapy combination of ipilimumab and nivolumab given alone in patients with positive
PD-L1 expression [10,11] or with 2 cycles of chemotherapy regardless of PD-L1 expression [12] has also been approved
by the US FDA, increasing the first-line armamentarium for the treatment of patients with NSCLC.
Identification of activating genomic alterations involving specific tyrosine kinases, particularly in lung adeno-
carcinoma coupled with the corresponding respective tyrosine kinase inhibitors, has led to a paradigm shift in the
treatment of NSCLC. Targeted therapies are now considered the preferred initial treatment for NSCLC patients
with EGFR and BRAF activating mutations as well as ALK, ROS1, NTRK, RET fusions and MET exon14 splicing
site mutations [13–15]. Molecular profiling of NSCLC tumors is recommended by international consensus guidelines
as part of routine evaluation in newly diagnosed patients to identify not only EGFR, ALK and ROS1, but a broader
panel of potentially actionable genes including BRAF, MET, RET, HER2 and KRAS [13].
Several studies have suggested that NSCLC patients with driver oncogenes may benefit less from chemotherapy-
immunotherapy combinations and a recent multi-disciplinary roundtable discussion recommended that immune
checkpoint inhibitors should be used after targeted therapies and chemotherapy [16]. However, it is not yet clear
whether these observations extend to NSCLC patients with RET fusions as the reported data are variable [17–19].
Additional studies are needed to fully characterize the effect of chemotherapy-immunotherapy combinations in
RET fusion-positive NSCLC patients.
RET gene fusions in NSCLC
The RET receptor tyrosine kinase can be abnormally activated by chromosomal rearrangements producing RET
gene fusions in 1–2% of patients with NSCLC [20–24]. RET rearrangements can occur with various upstream fusion
partners, detailed in Figure 1. In NSCLC, the most common RET fusion partners are KIF5B (most common)
and CCDC6. These RET alterations induce ligand independent RET kinase activity, which causes aberrant RET
activation and drives oncogenesis [25,26].
Selpercatinib
Selpercatinib (LOXO-292) is a novel, highly selective and potent, small-molecule inhibitor of RET signaling that was
recently granted accelerated approval by the US FDA for adult patients with metastatic RET fusion-positive NSCLC.
Selpercatinib has nanomolar potency against wild-type RET and other RET alterations, including the KIF5B-RET
fusion and V804M gatekeeper mutation, in both enzyme and cellular assays, with minimal activity against other
kinase and nonkinase targets [27,28]. A Phase I/II clinical trial LIBRETTO-001 showed that selpercatinib is
clinically active in patients with RET-altered solid tumors (in particular RET rearranged NSCLC and papillary
thyroid cancer and RET mutation positive papillary thyroid cancer), including those that have metastasized to the
CNS [29,30]. Treatment with selpercatinib resulted in a 64% objective response rate (ORR) (95% CI: 54–73%)
by blinded independent review in the registration dataset (n = 105) of patients with RET fusion-positive NSCLC
who previously received platinum-based chemotherapy and an 85% ORR (95% CI: 70–94%) in treatment-
naive patients with RET fusion-positive NSCLC (n = 39). Although the duration of response (DOR) and PFS
were not yet mature in treatment-naive patients, in patients who previously received chemotherapy, the median
DOR was 17.5 months (95% CI: 12–not estimable). Additionally, in patients previously treated with platinum-
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based chemotherapy, selpercatinib demonstrated a robust CNS ORR of 91% (95% CI: 59–100%) per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in 10 of 11 patients; all responders had a DOR of
≥6 months [29,31].
In 144 patients with RET fusion-positive NSCLC from the LIBRETTO-001 trial, the most common adverse
reactions included diarrhea (48%), dry mouth (41%), hypertension (31%), increased aspartate aminotransferase
(AST) level (30%), fatigue (29%), increased alanine transferase (ALT) level (26%), constipation (26%), nausea
(26%), peripheral edema (24%), urinary tract infection (22%) and headache (21%) [29]. The majority of adverse
reactions were Grade 1 or Grade 2. Grades 3–4 events occurring in ≥2% of patients included hypertension (14%),
increased ALT level (12%), increased AST level (10%), hyponatremia (6%), lymphopenia (6%), prolonged QT
corrected interval (5%), urinary tract infection (5%), diarrhea (3%), dyspnea (2%) and thrombocytopenia (2%).
The safety profile was similar to the overall safety profile for all patients, regardless of tumor type, who received
selpercatinib.
The LIBRETTO-431 clinical trial
LIBRETTO-431 (also referred to as J2G-MC-JZJC) is a global, open-label, randomized, controlled Phase III
trial, evaluating selpercatinib versus chemotherapy with cisplatin/carboplatin and pemetrexed treatment with or
without pembrolizumab in treatment-naive patients with locally advanced or metastatic RET fusion-positive non-
squamous NSCLC (NCT04194944). This study is active and recruiting participants, with planned enrollment at
approximately 230 sites across 26 countries.
Background & rationale
In the LIBRETTO-001 Phase I/II single arm trial, selpercatinib treatment demonstrated clinically meaningful
responses and sustained antitumor activity with a manageable profile in both heavily pre-treated and treatment-
naive RET fusion-positive NSCLC patients [29,32]. Although the strength of the data has led to accelerated FDA
approval in the US, it remains important to confirm these results in a randomized study [33] and this will be a key
consideration for approval and reimbursement in many countries around the world. However, given the strength
of the preliminary data it is also be important to minimize the number of patients assigned to the control arm.
As a result, the protocol was designed with a randomization factor of 2:1 in favor of the experimental arm and an
overall sample size of 250 patients.
The control arm will consist of platinum-based therapy (cisplatin or carboplatin) with pemetrexed, with or
without pembrolizumab, which is considered a SOC of nonsquamous NSCLC patients without EGFR mutations
or ALK fusions. Not all patients are suitable to receive an immune checkpoint inhibitor such as pembrolizumab
(e.g., patients with a history of interstitial lung disease or interstitial pneumonitis, an active autoimmune disease or
requiring concurrent treatment with supraphysiologic doses of immunosuppressive agents). Additionally, there are
geographical differences in frequency with which pembrolizumab is used based on individual patient characteristics
(e.g., contraindications, PD-L1 expression, the potential for subsequent therapy with targeted agents whose toxicity
profile may be affected by prior treatment with pembrolizumab) [34–37]. The design of LIBRETTO-431, which
will allow the platinum doublet to be administered with or without pembrolizumab, provides flexibility for the
investigator to select the regimen best suited for each specific patient in the control arm.
Study design
This study will be a head-to-head comparison of selpercatinib versus an SOC regimen for the treatment of advanced
or metastatic nonsquamous NSCLC, consisting of a baseline (screening) period, on-study treatment period with
an optional crossover treatment phase (only Arm B patients) and poststudy follow-up period (Figure 2). During
the baseline phase, patient eligibility and baseline characteristics will be determined using medical history, physical
exam, clinical laboratory testing and tumor assessments. Prior to enrollment, the presence of the RET gene fusion
must be confirmed in the tumor (by next generation sequencing and/or PCR) or in the blood (by next generation
sequencing) using a sponsor enabled or locally qualified test. If available, an archived tumor sample is required
for retrospective central confirmation of RET fusion. Patients will be stratified by geographic region (East Asian
vs nonEast Asian), brain metastases per investigator assessment (presence vs absence) and intended treatment if
randomized to Arm B (± pembrolizumab). Investigator’s choice/intent of treatment regimen must be declared
prior to randomization. After confirmation of eligibility, approximately 250 patients will be randomly assigned at
a ratio of 2:1 into one of the 2 arms:
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Geography: (East Asian vs non-East Asian)
Brain metastases: (presence vs absence)










unacceptable toxicity, or death
Selpercatinib
160 mg BID
Pemetrexed (500 mg/m2 Q3W)
+
Physician’s choice of:
Carboplatin (AUC 5 Q3W, 4 cycles)
or
Cisplatin (75 mg/m2 Q3W, 4 cycles)
+/- pembrolizuma† (200 mg Q3W)
Optional: cross-over


































Figure 2. LIBRETTO-431 study design.
†No more than 20% of patients with intent not to receive pembrolizumab will be enrolled.
AUC: Area under the concentration versus time curve; BICR: Blinded independent central review; BID: Twice a day; ECOG PS: Eastern
Cooperative Oncology Group performance status; NSCLC: Non-small-cell lung cancer; PD: Progressive disease; Q3W: Every 3 weeks.
• Arm A: treated with selpercatinib (160 mg twice a day [BID] continuously in 21-day cycles)
• Arm B: treated with pemetrexed (500 mg/m2 intravenous [iv.]) every 3 weeks plus the investigator’s choice of
the following treatments administered every 3 weeks:
• Four cycles of carboplatin (area under the concentration vs time curve [AUC] 5, maximum dose 750 mg iv.)
or cisplatin (75 mg/m2 iv.).
• With or without pembrolizumab (200 mg iv.) up to 35 cycles.
The on-study treatment phase will begin at randomization and continue until disease progression, development
of unacceptable toxicity, the start of a new anticancer therapy, withdrawal of consent, death or study completion.
Patients randomly assigned to Arm B who have radiographic disease progression confirmed by blinded independent
central review (BICR) will be eligible for crossover to selpercatinib. Crossover treatment will be optional at the
discretion of the investigator.
The post-treatment phase will consist of a short-term follow-up period that will begin when the patient and inves-
tigator decide the patient will no longer continue study therapy, until completing a safety assessment (30 ± 7 days)
after receiving the last dose of study treatment. Long-term follow-up will begin when the short-term follow-up
period is complete and will continue until death, study withdrawal, the patient is lost to follow-up, or final study
completion. Patients discontinuing prematurely from the study for any reason will complete adverse event and other
safety assessments. Information related to patient survival, disease progression, and poststudy anticancer therapy
details will be collected from the end of short-term follow-up until death or study completion. Patient-reported
questionnaires will be administered to assess patient reported health outcomes including health-related quality of
life, patient functioning, health status, disease symptoms and toxicities.
Objectives & end points
The study objectives are detailed in Table 1. The primary end points of PFS (per RECIST version 1.1) as assessed
by the BICR in patients intended for treatment with pembrolizumab (if assigned to control) will act as a gatekeeper
for the other primary end points of PFS by independent review in the intent-to-treat (ITT) population. For ease
of discussion, the 2 analysis populations will be referred to as the ITT-pembrolizumab and ITT populations,
respectively. PFS in the ITT population will be tested conditionally on achieving statistical significance for PFS
in the ITT-pembrolizumab population. Secondary end points include investigator assessed PFS, investigator and
BICR assessed ORR/DOR, intracranial ORR/DOR, time to deterioration in pulmonary symptoms, progression
after the next line of therapy, overall survival, RET fusion status (local vs central) and safety/tolerability.
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Table 1. Study objectives.
Primary
• To compare PFS of selpercatinib with the combination of platinum-based (carboplatin or cisplatin) therapy, pemetrexed and pembrolizumab
• To compare PFS of selpercatinib with the combination of platinum-based (carboplatin or cisplatin) and pemetrexed therapy, with or without pembrolizumab
Secondary
• To compare efficacy and safety/tolerability of selpercatinib with platinum-based and pemetrexed therapy with pembrolizumab
• To compare efficacy and safety/tolerability of selpercatinib with platinum-based and pemetrexed therapy with or without pembrolizumab
• To assess/evaluate performance of RET local laboratory tests compared with a single central test
PFS: Progression-free survival.
Table 2. Key eligibility criteria for LIBRETTO-431.
Inclusion criteria Exclusion criteria
Locally advanced or metastatic NSCLC
• Histologically or cytologically confirmed Stage IIIB-IIIC or Stage IV NSCLC that is
not suitable for radical surgery/radiation therapy
• Histology of the tumor must be predominantly nonsquamous
• Squamous cell and/or mixed small cell/non-small-cell histology is not permitted
Patient characteristics
• Measurable disease per RECIST 1.1
• ECOG PS of 0–2
• Life expectancy of at least 3 months
• Adequate organ function
RET alteration
Must have a RET gene fusion in tumor (by PCR or NGS) or in blood (by NGS) using
a qualified test
Medical conditions
• Additional known validated oncogenic drivers in NSCLC
• Symptomatic CNS involvement, carcinomatous meningitis or untreated spinal cord
compression
• Patients must be neurologically stable and previous treatment must be completed
at least 2 weeks prior to randomization
• Active cardiovascular disease or history of myocardial infarction ≤6 months prior
to start of treatment or prolongation of the QT interval corrected for heart rate
using QTcF 470 msec on more than 1 ECG obtained during the baseline period
• Uncontrolled, disease-related, pericardial effusion or pleural effusion
• Active, uncontrolled, systemic bacterial, viral or fungal infection that requires
treatment
• Serious ongoing intercurrent illness that is not controlled, despite optimal
treatment
• Clinically significant active malabsorption syndrome or other condition likely to
affect gastrointestinal absorption of the study drug
• Other malignancy unless nonmelanoma skin cancer, carcinoma in situ of the cervix
or other in situ cancers, or a malignancy diagnosed ≥2 years previously and not
currently active
Prior therapy
• Prior systemic therapy (chemotherapy, immunotherapy or biological therapy) for
metastatic disease
• Patients who received adjuvant or neoadjuvant therapy are eligible if such therapy
was completed ≥6 months prior to randomization
• Major surgery within 3 weeks prior to planned start of study treatment
• Palliative radiotherapy within 1 week of the first dose or any radiotherapy within
6 months prior to the first dose if 30 Gy to the lung
• Are taking a concomitant medication that is known to cause QTc prolongation
Patients on pembrolizumab
• History of interstitial lung disease or interstitial pneumonitis
• Active autoimmune disease or any illness that could compromise immune system
in last 2 years
• Use of escalating or chronic supraphysiologic doses of corticosteroids or
immunosuppressive agents
ECOG PS: Eastern Cooperative Oncology Group performance status; Gy: Gray; NGS: Next generation sequencing; NSCLC: Non-small-cell lung cancer; QTcF: QT interval corrected for heart
rate using Fridericia’s formula; RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1.
Key eligibility criteria
Key eligibility criteria are summarized in Table 2 and below. Eligible participants must have nonsquamous Stage IIIB-
IIIC not suitable for radical surgery/radiation therapy or Stage IV NSCLC, a RET gene fusion, measurable disease
and have an Eastern Cooperative Oncology Group performance status of 0–2, Participants will be excluded from the
study if any of the following criteria apply: presence of additional validated oncogenic drivers in NSCLC, received
prior systemic therapy for metastatic disease, symptomatic CNS involvement, active cardiovascular disease or
uncontrolled disease related pericardial effusion or pleural effusion.
Planned sample size
The planned sample size is approximately 250 patients who will be randomized at a ratio of 2:1 to selpercatinib or
control arms (i.e., 167 and 83 patients, respectively). To ensure adequate power for the test of treatment effect in
the ITT-pembrolizumab population, no more than 20% of patients with the intent to not receive pembrolizumab
if randomized to the control arm will be enrolled (e.g., no more than 50 patients with intent not to receive
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Table 3. Doses & dosing schedule.
Arm A (selpercatinib) Arm B (Investigator’s discretion of carboplatin or cisplatin + pemetrexed ± pembrolizumab)
Selpercatinib Carboplatin Cisplatin Permetrexed Pembrolizumab
(investigator’s choice)
Dose 160 mg AUC 5 (maximum dose
750 mg)
75 mg/m2 500 mg/m2 (with vitamin
supplementation)
200 mg
Schedule BID continuously in
21-day cycles
Day 1 Q3W for 4 cycles Day 1 Q3W for 4 cycles Day 1 Q3W Day 1 Q3W up to 35 cycles
Route Oral iv. iv. iv. iv.
AUC: Area under the concentration vs time curve; BID: Twice a day; iv.: Intravenous; Q3W: Every 3 weeks.
pembrolizumab). The study was started in March 2020 and the estimated primary and study completion dates are
December 2023 and April 2026, respectively.
Dose & schedule of therapy
Patients in Arm A will receive selpercatinib (160 mg BID, oral) administered in continuous 21-day cycles. Patients
in Arm B will receive pemetrexed (500 mg/m2, iv.) administered every 3 weeks plus the investigator’s choice of
carboplatin (AUC 5, maximum dose 750 mg, iv.) or cisplatin (75 mg/m2, iv.) administered every 3 weeks for 4
cycles. For patients in Arm B, at the investigator’s discretion, pembrolizumab (200 mg, iv.) may also be given for
up to 35 cycles. After the completion of 4 cycles of chemotherapy without progressive disease, patients assigned to
Arm B may receive maintenance therapy with pemetrexed (500 mg/m2) with or without pembrolizumab (200 mg)
every 3 weeks. Treatment will continue until radiographic disease progression confirmed by BICR, unacceptable
toxicity, withdrawal of consent or death. Dosing and treatment durations for all intervention groups are outlined
in Table 3.
Efficacy evaluations
To evaluate PFS, radiographic tumor assessments will be performed per RECIST 1.1. Scans should be obtained
within 28 days of baseline and then during the study treatment at approximately 6, 12, 21, 30, 39 and 48 weeks
after the start of dosing, then every 12 weeks thereafter until progression, the start of a new anticancer therapy,
death or study completion. Response assessments, will be evaluated by the BICR. These data will constitute the
primary assessment for PFS and ORR analyses.
Safety evaluations
Safety evaluations including electrocardiogram, physical examination with vital signs, clinical laboratory testing
(hematology, clinical chemistry, coagulation and urinalysis) and hepatic safety monitoring will be assessed at
scheduled intervals. Adverse events will be assessed continuously throughout the study duration.
Statistical analyses
Patient demographics, baseline disease characteristics, prior anticancer therapies, historical illness and pre-existing
conditions will be summarized. Descriptive statistics (i.e., number of patients, mean, median, standard deviation,
minimum and maximum) will be used for continuous variables. Categorical variables will be reported by frequency
and the corresponding percentage. The primary end points of BICR PFS will be estimated using the Kaplan–Meier
method and comparison between treatment arms will be assessed using the Cox proportional hazard regression and
log-rank test, stratified by the randomization strata. Under the current statistical assumptions, the study will deliver
approximately 90% power at a 2-sided type alpha level of 0.05. The study will be considered positive if a statistically
significant improvement in PFS in the ITT-pembrolizumab population is observed. ORR will be summarized for
each treatment arm. ORR and CNS ORR will be compared between Arm A and Arm B using a Cochran–Mantel–
Haenszel test stratified by the randomization strata. DOR according to both BICR and investigator assessed best
overall response (BOR) will be evaluated.
Conclusion
The LIBRETTO-431 Phase III trial outlined here will evaluate selpercatinib in comparison to chemotherapy
with carboplatin or cisplatin and pemetrexed with or without pembrolizumab in treatment-naive patients with
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advanced or metastatic RET fusion-positive nonsquamous NSCLC. The findings of this study will help define the
benefit of selpercatinib used as first-line therapy in patients with RET fusion-positive NSCLC. It is also expected
to demonstrate the importance of upfront broad-based genomic testing of newly diagnosed patients with NSCLC
for molecular alterations including RET fusions and will define the optimal therapy for this population.
Executive summary
Background
• Lung cancer is the leading cause of cancer death worldwide, with non-small-cell lung cancer (NSCLC) accounting
for approximately 80–85% of all lung cancers.
• Standard-of-care first-line treatment, platinum-based chemotherapy ± an immune checkpoint inhibitor, is not
specific in targeting the primary driver alteration in patients with RET fusion-positive NSCLC.
• The identification of mutually exclusive, activating genetic alterations in specific tyrosine kinases has led to a new
classification of NSCLC based on molecular genotype rather than histology. Patients with RET fusion-positive
NSCLC represent a population with a high unmet need.
Selpercatinib
• Selpercatinib (LOXO-292) is a highly potent and specific small-molecule inhibitor of the RET kinase, with minimal
inhibition of other kinase and nonkinase targets.
• Selpercatinib was designed to inhibit RET signaling as well as anticipated acquired resistance mechanisms that
could otherwise limit the activity of this therapeutic approach.
• In the LIBRETTO-001 Phase I/II trial, selpercatinib treatment demonstrated clinically meaningful responses and
sustained antitumor activity with a manageable toxicity profile in both heavily pretreated and treatment-naive
patients, including patients with brain metastases, with RET fusion-positive NSCLC.
LIBRETTO-431 study
• The global, open-label, randomized, controlled, Phase III LIBRETTO-431 trial, will evaluate selpercatinib versus
platinum-based and pemetrexed treatment with or without pembrolizumab in treatment-naive patients with
locally advanced or metastatic RET fusion-positive nonsquamous NSCLC (NCT04194944).
• First ever randomized Phase III clinical trial in treatment-naive RET fusion-positive NSCLC.
Conclusion
• The results of this important trial will help further define the role of selpercatinib as a front-line treatment for
people living with advanced or metastatic RET fusion-positive NSCLC.
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The LIBRETTO-431 Trial
A Phase III study comparing selpercanib to planum-based and pemetrexed therapy with or without










Stage IIIB-IIIC not suitable
for radical surgery/radiaon
therapy or Stage IV non-
small cell lung cancer
RET fusion posive
RET fusion posive
idenfied by PCR or NGS
(tumor) or NGS (blood)
≥ 18 years old
Have measurable disease
by RECIST 1.1; an ECOG PS










The primary endpoint of PFS per
RECIST v1.1 by BICR in paents
with intent to receive
pembrolizumab will act as a 
gatekeeper for the endpoint of
PFS by independent review in the
intent-to-treat populaon

















will be assessed prior to trial
enrollment
NCT04194944
This study is acve and recruing parcipants, with planned enrollment at approximately 230 sites across 26 countries.













 Geography: (East Asian vs non-East Asian)
 Brain metastases: (presence vs absence)
 Intended treatment (Arm B) (+/- pembrolizumab)
Pemetrexed (500 mg/m2 Q3W)
+
Physician’s choice of:
Carboplan (AUC 5 Q3W, 4 cycles)
or
Cisplan (75 mg/m2 Q3W, 4 cycles)



























Screening On-study treatment Follow-up
*Paents with the intent not to receive pembrolizumab
(by invesgators' choice at the me of randomizaon) will
be restricted to 20%
Solomon et al. Future Oncology (2020) www.futuremedicine.com/doi/10.2217/fon-2020-0935
Glossary: AUC: Area under the concentraon versus me curve; BICR: Blinded independent review commiee; BID: Twice a day; CNS: Central nervous system; DOR: Duraon of response; ECOG PS: Eastern Cooperave Oncology Group
performance status; NSCLC: Non-small cell lung cancer; ORR: Objecve response rate; OS: Overall survival; PD: Progressive disease; PFS: Progression free survival; PFS2: Progression aer the next line of therapy; Q3W: Every 3 weeks;
RECIST 1.1 = Response Evaluaon Criteria In Solid Tumours version 1.1
The study will be considered posive if a 
stascally significant improvement in PFS in the
ITT-pembrolizumab populaon is observed
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